Quarterly Result28 Jan 2026, 05:33 pm
Gland Pharma Posts Strong Q3 FY26 Results with 22% YoY Growth in Revenue and 37% adj. PAT Growth
AI Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the third quarter ended December 31, 2025. The company reported a 22% year-on-year growth in revenue and a 37% growth in adjusted Profit After Tax (PAT). The strong performance was driven by robust year-on-year revenue growth in the US and Europe markets, and steady improvement in margins. The company also highlighted the contribution of Cenexi's breakeven and strong revenue traction in the base business.
Key Highlights
- Quarterly revenue increased by 22% year-on-year
- Quarterly adj. EBITDA increased by 25% year-on-year
- Quarterly adj. PBT increased by 29% year-on-year
- Quarterly adj. PAT increased by 37% year-on-year
- Strong performance in US and Europe markets